SCHEMBL4019723

SCHEMBL4019723

Cc1ccccc1C(=O)c1c(C)cccc1N

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 5/20 0.51
MAPK12 P53778 5/20 0.51
MAPK11 Q15759 5/20 0.51
MAPK14 Q16539 5/20 0.51
MYC P01106 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CYP3A4 P08684 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
HSD17B10 Q99714 2/20 0.43
CFTR P13569 1/20 0.43
CYP2C9 P11712 1/20 0.42
KMT2A Q03164 1/20 0.42
CD44 P16070 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5562623 0.86 CDK2 (0.50) MAPK13MAPK12MAPK11MAPK14MYC
SCHEMBL7041793 0.86 CYP3A4 (0.48) MYCALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL1913492 0.83 MAPT (0.55) MAPK13MAPK12MAPK11MAPK14GAA
SCHEMBL538169 0.82 GAA (0.59) MAPK13MAPK12MAPK11MAPK14MYC
SCHEMBL2230263 0.82 CYP3A4 (0.50) MAPK13MAPK12MAPK11MAPK14MYC
SCHEMBL28403451 0.81 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14MYC
SCHEMBL14454155 0.78 CDK2 (0.48) MAPK14MYCGAAMAPTALDH1A1
SCHEMBL4023452 0.78 CYP3A4 (0.44) MAPK13MAPK12MAPK11MAPK14MYC
SCHEMBL29387256 0.77 CYP3A4 (0.55) MAPK13MAPK12MAPK11MAPK14GAA
SCHEMBL333141 0.77 CYP3A4 (0.55) MAPK13MAPK12MAPK11MAPK14GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061755-A1 TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-05-27 EP disclosed
US-20090069408-A1 TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-03-12 US disclosed
WO-2008109840-A1 TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069408-A1 TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS TFRC, SLC40A1, FECH MAPK13 3680/4885MAPK12 4116/4885MAPK11 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.